Measles, mumps, and rubella in Finland: 25 years of a nationwide elimination programme (Q34884995)

5 August 2017

1 reference

title

Measles, mumps, and rubella in Finland: 25 years of a nationwide elimination programme (English)

1 reference

5 August 2017

0 references

1 reference

1 reference

1 reference

Heikki Peltola

1

1 reference

5 August 2017

Sari Jokinen

2

1 reference

5 August 2017

Mikko Paunio

3

1 reference

5 August 2017

Tapani Hovi

4

1 reference

5 August 2017

Irja Davidkin

5

1 reference

5 August 2017

1 December 2008

1 reference

Lancet Infectious Diseases

5 August 2017

1 reference

5 August 2017

8

1 reference

5 August 2017

12

1 reference

5 August 2017

796-803

1 reference

IMMUNITY IN MUMPS : VI. EXPERIMENTS ON THE VACCINATION OF HUMAN BEINGS WITH FORMOLIZED MUMPS VIRUS

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

Mumps vaccination in the Finnish defense forces

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

No measles in Finland

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

Mumps and rubella eliminated from Finland

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

Rapid effect on endemic measles, mumps, and rubella of nationwide vaccination programme in Finland

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

Acute infections, infection pressure, and atopy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

No evidence for measles, mumps, and rubella vaccine-associated inflammatory bowel disease or autism in a 14-year prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: a 12-year follow-up in two cohorts

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination. A 15-year follow-up in Finland

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

Allergic reactions to measles-mumps-rubella vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

Risk of Guillain-Barré syndrome after measles-mumps-rubella vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

Neurologic disorders after measles-mumps-rubella vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

Twice vaccinated recipients are better protected against epidemic measles than are single dose recipients of measles containing vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

IgG avidity to distinguish secondary from primary measles vaccination failures: prospects for a more effective global measles elimination strategy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

Etiology of measles- and rubella-like illnesses in measles, mumps, and rubella-vaccinated children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

Etiology of mumps-like illnesses in children and adolescents vaccinated for measles, mumps, and rubella

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

Increase of vaccination coverage by mass media and individual approach: intensified measles, mumps, and rubella prevention program in Finland

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

The clinical significance of measles: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

1 reference

7 January 2021

Cellular immunity to mumps virus in young adults 21 years after measles-mumps-rubella vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

Effect of measles, mumps, rubella vaccination on pattern of encephalitis in children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

Rubella immunity and morbidity: impact of different vaccination programs in Finland 1979-1992.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 São Paulo epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

Measles in Minsk, Belarus, 2001-2003: clinical, virological and serological parameters

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

Mumps vaccine performance among university students during a mumps outbreak

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

Duration of humoral immunity to common viral and vaccine antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

Mumps outbreaks in Canada and the United States: time for new thinking on mumps vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

Recent resurgence of mumps in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

Medicine and the media: MMR: the scare stories are back

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

Two successive outbreaks of mumps in Nova Scotia among vaccinated adolescents and young adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970282-2

7 January 2021

10.1016/S1473-3099(08)70282-2

Identifiers

DOI

1 reference

5 August 2017

1 reference